Clinical trials
Acute Graft Versus Host Disease clinical trials
Below are recruiting acute graft versus host disease clinical trials, each written for real people, not researchers. We’re tracking 84 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06321198Recruiting
Modified stem cells for severe graft-versus-host disease
This trial tests a new type of stem cell therapy (iMSC) for people with steroid-resistant acute graft-versus-host disease (aGVHD), a serious complication after a stem cell transplant. The goal is to see if it's safe and might help control the disease.
Hefei, AnhuiAges 4–70 - NCT06300320RecruitingPhase 2
TQ05105 for chronic graft-versus-host disease
This trial is testing an investigational drug called TQ05105 for people with moderate to severe chronic graft-versus-host disease (GVHD) after a stem cell transplant. It may offer a new treatment option if current therapies are not working well enough.
Hefei, AnhuiAges 18–70 - NCT06294691RecruitingPhase 3
Timing of stem cell infusion to prevent GVHD in blood cancer
This study is testing whether the timing of a stem cell infusion affects the chance of developing graft-versus-host disease (aGVHD), a common complication after transplant. It may help make transplants safer for people with blood cancers.
Hefei, AnhuiAges 12–60 - NCT06252870RecruitingPhase 2
Comparing two conditioning regimens for stem cell transplant
This trial tests two different chemotherapy and radiation plans (conditioning regimens) given before a stem cell transplant from a matched donor. Both are followed by the same drugs to prevent graft-versus-host disease. The goal is to find which regimen works better for people with blood cancers.
AngersAges 18–70 - NCT06233110RecruitingPhase 1
Ruxolitinib and fostamatinib for steroid-resistant chronic GVHD
This study tests two drugs, ruxolitinib and fostamatinib, together for people with chronic graft-versus-host disease (GVHD) that hasn't responded well to steroids. The goal is to see if this combination can better control GVHD.
Durham, North CarolinaAges 18–80 - NCT06128070RecruitingPhase 2
Preventing GVHD after stem cell transplant for leukemia
This trial tests adding ruxolitinib to standard drugs (tacrolimus and methotrexate) to prevent graft-versus-host disease in children and young adults undergoing a stem cell transplant for acute leukemia or myelodysplastic syndrome. The goal is to lower the risk of GVHD and improve transplant outcomes.
Duarte, CaliforniaAges 2–22 - NCT06008808RecruitingPhase 1
Ruxolitinib and abatacept to prevent GVHD after haplo transplant
This trial tests whether a drug called ruxolitinib, with or without another drug called abatacept, can prevent graft-versus-host disease and cytokine release syndrome after a half-matched stem cell transplant from a family donor. It's for people with certain blood cancers who are getting this type of transplant.
St Louis, MissouriAges 18 years+ - NCT05996627RecruitingPhase 2
Belumosudil for early treatment of chronic graft-versus-host disease
This trial tests a pill called belumosudil to see if it can help people with chronic graft-versus-host disease (a common complication after a stem cell transplant where donor cells attack your body). It is for patients who have symptoms but are not yet on strong immune-suppressing drugs.
Duarte, CaliforniaAges 18 years+ - NCT03819803RecruitingPhase 3
Fecal transplant for gut graft-versus-host disease
This study tests whether restoring healthy gut bacteria using a fecal microbiota transplant can improve steroid-refractory gut graft-versus-host disease (aGvHD) after stem cell transplant. If your gut symptoms are your first episode and your stool bacteria diversity is low, this trial may be an option worth screening for.
Graz, StyriaAges 18–70 - NCT05718791Recruiting
Testing blood markers to predict graft-versus-host disease
This trial looks at two blood markers to predict the risk of acute graft-versus-host disease after an allogeneic stem cell transplant. If you qualify, your care team may use results to help anticipate and manage complications earlier.
Detroit, MichiganAges 18–80 - NCT05531786RecruitingPhase 1/Phase 2
Pacritinib for hard-to-treat chronic graft-versus-host disease
This early-phase study tests pacritinib, a targeted medicine, for chronic graft-versus-host disease (cGVHD) that hasn’t improved after prior treatments. If you qualify, the goal is to reduce cGVHD symptoms and improve how well you function after a stem cell transplant.
Miami, FloridaAges 18–120 - NCT05470491RecruitingPhase 1/Phase 2
Haploidentical bone marrow transplant with GVHD prevention drugs
This trial tests a reduced-intensity bone marrow transplant from a related donor (haploidentical), using medicines to help prevent a serious complication called GVHD. It is for people with certain blood cancers and aims to improve outcomes by balancing transplant benefit with lower treatment intensity.
Bethesda, MarylandAges 12–120 - NCT05436418RecruitingPhase 1/Phase 2
Lower-dose transplant medicines to prevent graft-versus-host disease
This early-phase study tests a lower dose of cyclophosphamide given after a stem cell transplant to prevent graft-versus-host disease (GVHD). It also uses sirolimus and mycophenolate to improve how well the donor immune system accepts the transplant, aiming to reduce side effects while keeping protection against GVHD.
Duarte, CaliforniaAges 12–120 - NCT05443425RecruitingPhase 1
Leflunomide plus steroids for acute graft-versus-host disease
This early-phase trial tests whether adding leflunomide to standard steroid treatment can better control acute graft-versus-host disease (aGvHD) after a stem cell transplant. It may help reduce the immune reaction that damages the body while keeping treatment safe and manageable.
Duarte, CaliforniaAges 18 years+ - NCT05289167RecruitingPhase 1/Phase 2
Medicines to prevent graft-versus-host disease after a transplant
This trial tests a combination of medicines (post-transplant cyclophosphamide, bortezomib, and abatacept) to lower your chance of developing graft-versus-host disease (when transplanted immune cells attack your body) after a transplant. If you qualify, you’ll receive the study medicines as part of your post-transplant care and be followed closely to check safety and prevention of GvHD.
New Hyde Park, New YorkAges 14–100 - NCT05236062Recruiting
Exercise during steroid treatment for GVHD
This study looks at whether doing moderate-to-vigorous exercise can reduce complications from corticosteroids in people with newly diagnosed GVHD. It may help your body tolerate steroids better, while checking exercise safety during treatment.
Boston, MassachusettsAges 18 years+ - NCT05067595RecruitingPhase 1
Fecal transplant and fiber for gut graft-versus-host disease
This study tests whether a fecal microbiota transplant (a procedure that puts healthy donor bacteria into your gut) combined with a dietary fiber supplement can help treat gut graft-versus-host disease, a common complication after a stem cell transplant. It may help reduce diarrhea and other gut symptoms.
Seattle, WashingtonAges 18 years+ - NCT04745221Recruiting
Fecal microbes therapy to help prevent graft-versus-host disease
This trial studies a treatment made from donor gut microbes to help prevent a common complication after a transplant called acute graft-versus-host disease (aGVHD). It may help by improving the balance and variety of gut bacteria during recovery after haploidentical transplant.
Suzhou, JiangsuAges 18–60 - NCT04744116RecruitingEarly Phase 1
Cord blood cell therapy added to ruxolitinib for steroid-resistant GVHD
This trial studies whether adding cord-blood–derived cells to ruxolitinib can improve steroid-resistant acute graft-versus-host disease (GVHD) affecting the lower gut or liver. It’s meant for people who are not getting better (or are worsening) despite adequate steroid treatment.
Houston, TexasAges 12–80 - NCT04710576RecruitingPhase 2
Axatilimab for chronic graft-versus-host disease
This trial tests a new drug called axatilimab to help patients whose chronic graft-versus-host disease (a condition where transplanted immune cells attack the body) isn't responding well to standard treatments. Researchers want to find the right dose and see if it can improve symptoms and quality of life.
Birmingham, AlabamaAges 2 years+ - NCT04380740RecruitingPhase 2
Longer vs shorter abatacept doses to prevent graft-versus-host disease
This trial tests whether giving abatacept for a longer or shorter time can better prevent graft-versus-host disease (a common complication after a stem cell transplant). If you’re having a planned unrelated donor transplant, the results may help reduce the risk or severity of transplant-related immune problems.
Duarte, CaliforniaAges 2 years+ - NCT03970096RecruitingPhase 2
Reduce graft-versus-host disease after stem cell transplant
This Phase 2 study tests ways to lower the risk of graft-versus-host disease (GVHD), a serious complication after an allogeneic stem cell transplant from a matched donor. It is for people with acute leukemia or MDS who are going to receive intensive conditioning therapy, aiming to improve safety while keeping the transplant effective.
Tampa, FloridaAges 1–60 - NCT03148743Recruiting
Fecal transplant for gut graft-versus-host disease
This study tests whether a fecal transplant (FMT) can help treat gut graft-versus-host disease (gut GVHD), a condition where donated immune cells attack the intestines. If you have gut GVHD and meet age requirements, you may be eligible to receive this treatment in the trial.
Suzhou, JiangsuAges 10–60 - NCT00092235Recruiting
Understanding chronic graft-versus-host disease outcomes
This study follows patients who have had a stem cell transplant and developed chronic graft-versus-host disease (a condition where transplanted cells attack the body). Researchers will track your symptoms and collect blood samples to understand what affects how well patients do over time.
Bethesda, MarylandAges 1–120
Hear when a new Acute Graft Versus Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for acute graft versus host disease?
- Yes. Clin2 currently lists 84 recruiting acute graft versus host disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a acute graft versus host disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a acute graft versus host disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.